U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07778446) titled 'A Study to Test CRT-402 in Refractory Autoimmune Disease' on Aug. 06.
Brief Summary: Patients with refractory autoimmune diseases often have limited treatment options and ongoing disease activity despite standard therapies. CRT-402 is an in vivo Cluster of differentiation 19 (CD19)-targeted CAR-T cell therapy designed to deplete CD19-positive B cells and promote immune system reset. This study evaluates the safety, tolerability, preliminary efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) of CRT-402 in participants with active refractory systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammat...